目的:研究吉西他滨对人胰腺癌AsPC-1细胞体外生长的作用机制。方法:用脂质体转染法将含有p53正向凋亡调控因子(p53 upregulated modulator of apoptosis,PUMA)反义核酸的真核表达载体pcDNA3.1-PUMAAS和空载体pcDNA3.1导入AsPC-1细胞,G41...目的:研究吉西他滨对人胰腺癌AsPC-1细胞体外生长的作用机制。方法:用脂质体转染法将含有p53正向凋亡调控因子(p53 upregulated modulator of apoptosis,PUMA)反义核酸的真核表达载体pcDNA3.1-PUMAAS和空载体pcDNA3.1导入AsPC-1细胞,G418筛选阳性细胞,获得稳定转染的阳性克隆。将转染载体的AsPC-1阳性克隆细胞和未转染载体的AsPC-1细胞分别暴露于浓度为1、5、10和15μmol/L的吉西他滨溶液中作用72h。RT-PCR和Western印迹法检测不同组细胞经吉西他滨作用72h后的PUMA表达水平,MTT检测细胞生长抑制情况,FCM、Hoechst 33258荧光染色和TUNEL法检测细胞凋亡情况。结果:吉西他滨促进AsPC-1细胞凋亡,抑制细胞生长,并有明显的剂量依赖性,在细胞凋亡的同时伴有PUMA表达的上调;当细胞转染PUMA反义核酸抑制PUMA表达后,受吉西他滨作用的细胞中PUMA蛋白表达明显降低,同时伴有细胞凋亡的抑制及细胞增殖明显增加。结论:吉西他滨促进体外AsPC-1细胞凋亡,并抑制细胞生长,其诱导细胞凋亡与上调PUMA表达有关。展开更多
目的探讨p53正向细胞凋亡调控因子(p53up-regulated modulator of apoptosis protein,PUMA)/p53促凋亡蛋白(apoptosis stimulating protein of p53,ASPP)1融合基因及单个基因对胃癌SGC-7901细胞的杀伤作用。方法通过脂质体(lipofectamin...目的探讨p53正向细胞凋亡调控因子(p53up-regulated modulator of apoptosis protein,PUMA)/p53促凋亡蛋白(apoptosis stimulating protein of p53,ASPP)1融合基因及单个基因对胃癌SGC-7901细胞的杀伤作用。方法通过脂质体(lipofectamine)2000TM将PUMA/ASPP1融合基因及PUMA、ASPP1单个基因分别转染胃癌SGC-7901细胞系[实验设5组,分别为胃癌细胞无转染空白对照(SGC-7901)组,空载质粒转染细胞对照(SGC-7901-pcDNA3.1)组以及重组ASPP1质粒转染细胞实验(SGC-7901-ASPP1)组、重组PUMA质粒转染细胞实验(SGC-7901-PUMA)组、重组PUMA/ASPP1质粒转染细胞实验(SGC-7901-PUMA/ASPP1)组],再次经G418筛选,获得稳定表达融合基因SGC-7901-PUMA/ASPP1细胞株。通过MTT法及使用流式细胞仪测定各组胃癌SGC-7901系细胞的存活数(光吸收度即A值)及细胞周期。结果 SGC-7901组与SGC-7901-pcDNA3.1组A值比较差异无统计学意义(P>0.05);SGC-7901-ASPP1组、SGC-7901-PUMA组和SGC-7901-PUMA/ASPP1组A值明显低于SGC-7901组与SGC-7901-pcDNA3.1组(均P<0.01);SGC-7901-ASPP1组、SGC-7901-PUMA组和SGC-7901-PUMA/ASPP13组中,SGC-7901-PUMA/ASPP1细胞组A值最低(P<0.01)。与SGC-7901组、SGC-7901-pcDNA3.1组比较,SGC-7901-ASPP1、SGC-7901-PUMA、SGC-7901-PUMA/ASPP1组的G1期明显增多,S期明显减少,尤以SGC-7901-PUMA/ASPP1组S期减少为甚(均P<0.01);SGC-7901-pcDNA3.1组与SGC-7901组比较G1期、S期差异无统计学意义(P>0.05)。结论双抑癌基因可有效抑制胃癌SGC-7901系细胞增殖,双抑癌基因较单个抑癌基因具有更强的抗肿瘤作用。展开更多
P53正向细胞凋亡调控因子(P53 upregulated modulator of apoptosis,PUMA)是Bcl-2家族唯BH3结构域亚家族成员,位于线粒体内,可被多种损伤因素诱导激活。PUMA通过BH3结构域与Bcl-2样抗凋亡蛋白结合后发挥其促凋亡作用。PUMA抑制剂模拟蛋...P53正向细胞凋亡调控因子(P53 upregulated modulator of apoptosis,PUMA)是Bcl-2家族唯BH3结构域亚家族成员,位于线粒体内,可被多种损伤因素诱导激活。PUMA通过BH3结构域与Bcl-2样抗凋亡蛋白结合后发挥其促凋亡作用。PUMA抑制剂模拟蛋白间的结合作用,阻碍PUMA与Bcl-2样蛋白结合,凋亡被抑制。在体内,依小鼠肝脏缺血、再灌注时间不同,损伤情况各异。损伤较轻时,PUMA表达升高,PUMA抑制剂能够保护肝脏抵抗损伤;当损伤较严重时,PUMA表达升高不明显,PUMA抑制剂的保护作用也不明显。综合上述,在一定程度损伤的条件下,PUMA抑制剂可以有效地保护肝脏,减轻损伤。展开更多
AIM:To study the regulation effect of different cytokines combinations on stem cell or progenitor of umbilical blood when no blood serum and matrix exist. METHODS: Collect and analyze the 23 sample of umbilical blood....AIM:To study the regulation effect of different cytokines combinations on stem cell or progenitor of umbilical blood when no blood serum and matrix exist. METHODS: Collect and analyze the 23 sample of umbilical blood. RESULTS:(1) The combination of SCF+Flk2/Flt3 ligand and(FL)±TPO can amplify CD34,+,CD34+Thy 1+,CD34+CD33+and LTC IC in umbilical blood effectively and rapidly.(2) After add solubility type (sIL 6R)of IL 6 and IL 6 receptor into this combination, the stem cell or progenitor proliferated prominently;When add IL 6 alone(without sIL 6R), the content of CD34+cells and LTC IC didn’t increased obviously in early stage, but the amplification of CFU Mix and BFU E was not prominent as CFU GM. (3)Detect apoptosis rate of cells by FITC Annexin Ⅴlabeled by membranous change in early stage of cellular apoptosis. After add Flt3L and /or IL 6+sIL 6R, the Annexin Ⅴpositive cells decreased from 15.2%~19.1%to 2.8%~3.5%. CONCLUSION: In suspending system composed with SCF+TPO+Flt3L+IL 6+sIL 6R without matrix and blood serum, the umbilical blood can not only produce large amount of committed progenitor but also keep certain quantitive hematopoietic cells of early stage.展开更多
文摘目的探讨p53正向细胞凋亡调控因子(p53up-regulated modulator of apoptosis protein,PUMA)/p53促凋亡蛋白(apoptosis stimulating protein of p53,ASPP)1融合基因及单个基因对胃癌SGC-7901细胞的杀伤作用。方法通过脂质体(lipofectamine)2000TM将PUMA/ASPP1融合基因及PUMA、ASPP1单个基因分别转染胃癌SGC-7901细胞系[实验设5组,分别为胃癌细胞无转染空白对照(SGC-7901)组,空载质粒转染细胞对照(SGC-7901-pcDNA3.1)组以及重组ASPP1质粒转染细胞实验(SGC-7901-ASPP1)组、重组PUMA质粒转染细胞实验(SGC-7901-PUMA)组、重组PUMA/ASPP1质粒转染细胞实验(SGC-7901-PUMA/ASPP1)组],再次经G418筛选,获得稳定表达融合基因SGC-7901-PUMA/ASPP1细胞株。通过MTT法及使用流式细胞仪测定各组胃癌SGC-7901系细胞的存活数(光吸收度即A值)及细胞周期。结果 SGC-7901组与SGC-7901-pcDNA3.1组A值比较差异无统计学意义(P>0.05);SGC-7901-ASPP1组、SGC-7901-PUMA组和SGC-7901-PUMA/ASPP1组A值明显低于SGC-7901组与SGC-7901-pcDNA3.1组(均P<0.01);SGC-7901-ASPP1组、SGC-7901-PUMA组和SGC-7901-PUMA/ASPP13组中,SGC-7901-PUMA/ASPP1细胞组A值最低(P<0.01)。与SGC-7901组、SGC-7901-pcDNA3.1组比较,SGC-7901-ASPP1、SGC-7901-PUMA、SGC-7901-PUMA/ASPP1组的G1期明显增多,S期明显减少,尤以SGC-7901-PUMA/ASPP1组S期减少为甚(均P<0.01);SGC-7901-pcDNA3.1组与SGC-7901组比较G1期、S期差异无统计学意义(P>0.05)。结论双抑癌基因可有效抑制胃癌SGC-7901系细胞增殖,双抑癌基因较单个抑癌基因具有更强的抗肿瘤作用。
文摘P53正向细胞凋亡调控因子(P53 upregulated modulator of apoptosis,PUMA)是Bcl-2家族唯BH3结构域亚家族成员,位于线粒体内,可被多种损伤因素诱导激活。PUMA通过BH3结构域与Bcl-2样抗凋亡蛋白结合后发挥其促凋亡作用。PUMA抑制剂模拟蛋白间的结合作用,阻碍PUMA与Bcl-2样蛋白结合,凋亡被抑制。在体内,依小鼠肝脏缺血、再灌注时间不同,损伤情况各异。损伤较轻时,PUMA表达升高,PUMA抑制剂能够保护肝脏抵抗损伤;当损伤较严重时,PUMA表达升高不明显,PUMA抑制剂的保护作用也不明显。综合上述,在一定程度损伤的条件下,PUMA抑制剂可以有效地保护肝脏,减轻损伤。
文摘AIM:To study the regulation effect of different cytokines combinations on stem cell or progenitor of umbilical blood when no blood serum and matrix exist. METHODS: Collect and analyze the 23 sample of umbilical blood. RESULTS:(1) The combination of SCF+Flk2/Flt3 ligand and(FL)±TPO can amplify CD34,+,CD34+Thy 1+,CD34+CD33+and LTC IC in umbilical blood effectively and rapidly.(2) After add solubility type (sIL 6R)of IL 6 and IL 6 receptor into this combination, the stem cell or progenitor proliferated prominently;When add IL 6 alone(without sIL 6R), the content of CD34+cells and LTC IC didn’t increased obviously in early stage, but the amplification of CFU Mix and BFU E was not prominent as CFU GM. (3)Detect apoptosis rate of cells by FITC Annexin Ⅴlabeled by membranous change in early stage of cellular apoptosis. After add Flt3L and /or IL 6+sIL 6R, the Annexin Ⅴpositive cells decreased from 15.2%~19.1%to 2.8%~3.5%. CONCLUSION: In suspending system composed with SCF+TPO+Flt3L+IL 6+sIL 6R without matrix and blood serum, the umbilical blood can not only produce large amount of committed progenitor but also keep certain quantitive hematopoietic cells of early stage.